Shannon A Miller

Summary

Affiliation: Florida Hospital
Country: USA

Publications

  1. ncbi Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
    Shannon Miller
    Pharmacotherapy Faculty, Florida Hospital Family Practice Residency, Orlando, 32822, USA
    Ann Pharmacother 40:1336-43. 2006
  2. ncbi Angiotensin II vaccine: a novel approach in the treatment of hypertension
    Shannon A Miller
    Pharmacotherapy Faculty, Florida Hospital East Family Practice Residency, Orlando Campus, 7975 Lake Underhill Road, Suite 200, Orlando, Florida 32822, USA
    Expert Opin Biol Ther 8:1669-73. 2008
  3. ncbi Otelixizumab: a novel agent for the prevention of type 1 diabetes mellitus
    Shannon A Miller
    Florida Hospital East, Pharmacotherapy Faculty, Family Practice Residency, Family Health Center East, 7975 Lake Underhill Road, Suite 200, Orlando, FL 32822, USA
    Expert Opin Biol Ther 11:1525-32. 2011
  4. ncbi Albiglutide: a new GLP-1 analog for the treatment of type 2 diabetes
    Erin L St Onge
    University of Florida College of Pharmacy, Orlando Campus, 2725 S Binion Rd, Apopka, FL 32703 8504, USA
    Expert Opin Biol Ther 10:801-6. 2010
  5. ncbi Sitagliptin as combination therapy in the treatment of type 2 diabetes mellitus
    Shannon A Miller
    Pharmacotherapy Faculty, Florida Hospital East Family Practice Residency, Orlando, Florida, USA
    Diabetes Metab Syndr Obes 2:23-30. 2009

Collaborators

  • Erin L St Onge

Detail Information

Publications5

  1. ncbi Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
    Shannon Miller
    Pharmacotherapy Faculty, Florida Hospital Family Practice Residency, Orlando, 32822, USA
    Ann Pharmacother 40:1336-43. 2006
    ..To review the pharmacology, pharmacokinetics, safety, and efficacy of sitagliptin, a dipeptidyl peptidase IV (DPP-IV) inhibitor in the management of type 2 diabetes mellitus...
  2. ncbi Angiotensin II vaccine: a novel approach in the treatment of hypertension
    Shannon A Miller
    Pharmacotherapy Faculty, Florida Hospital East Family Practice Residency, Orlando Campus, 7975 Lake Underhill Road, Suite 200, Orlando, Florida 32822, USA
    Expert Opin Biol Ther 8:1669-73. 2008
    ..An ideal regimen would be a few subcutaneous injections per year, which in turn could vastly improve adherence and subsequent outcomes...
  3. ncbi Otelixizumab: a novel agent for the prevention of type 1 diabetes mellitus
    Shannon A Miller
    Florida Hospital East, Pharmacotherapy Faculty, Family Practice Residency, Family Health Center East, 7975 Lake Underhill Road, Suite 200, Orlando, FL 32822, USA
    Expert Opin Biol Ther 11:1525-32. 2011
    ..Adverse effects were significant but transient. Otelixizumab shows great promise but leaves room for improvement. Results of ongoing trials will help define its role in the prevention of T1DM...
  4. ncbi Albiglutide: a new GLP-1 analog for the treatment of type 2 diabetes
    Erin L St Onge
    University of Florida College of Pharmacy, Orlando Campus, 2725 S Binion Rd, Apopka, FL 32703 8504, USA
    Expert Opin Biol Ther 10:801-6. 2010
    ..This new class of medications provides the benefits of weight loss as well as a lack of hypoglycemia. However, the currently available agents require once or twice daily injections...
  5. ncbi Sitagliptin as combination therapy in the treatment of type 2 diabetes mellitus
    Shannon A Miller
    Pharmacotherapy Faculty, Florida Hospital East Family Practice Residency, Orlando, Florida, USA
    Diabetes Metab Syndr Obes 2:23-30. 2009
    ..It has also been shown to be highly tolerable, efficacious and with little risk of hypoglycemia. This review will focus on combination therapy with sitagliptin with emphasis on combination with metformin...